Creative Planning
VIR icon

Creative Planning’s Vir Biotechnology VIR Stock Holding History

Creative Planning’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
100,889
+378
+0.4% +$3.6K ﹤0.01% 2615
2026
Q1 		$901K Buy
100,511
+20,815
+26% +$166K ﹤0.01% 2546
2025
Q4 		$481K Buy
79,696
+27,020
+51% +$161K ﹤0.01% 2879
2025
Q3 		$301K Buy
52,676
+14,917
+40% +$76.3K ﹤0.01% 3143
2025
Q2 		$190K Buy
37,759
+25,760
+215% +$138K ﹤0.01% 3241
2025
Q1 		$77.8K Sell
11,999
-2,189
-15% -$19.5K ﹤0.01% 3288
2024
Q4 		$104K Buy
+14,188
New +$112K ﹤0.01% 3151
2024
Q3 		– Sell
-27,198
Closed -$242K – 3322
2024
Q2 		$242K Buy
27,198
+5,385
+25% +$51.6K ﹤0.01% 2525
2024
Q1 		$221K Buy
21,813
+4,657
+27% +$47.4K ﹤0.01% 2502
2023
Q4 		$173K Buy
+17,156
New +$157K ﹤0.01% 2476

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Creative Planning's VIR Position: Q2 2026 in Review

Creative Planning increased its Vir Biotechnology (VIR) stake by 0.38% in Q2 2026, buying an estimated $3.6K and bringing the position to 100,889 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2615.

Creative Planning first reported a position in VIR in Q4 2023 and has held it in 10 quarters since. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Creative Planning held 100,889 shares of Vir Biotechnology worth $1.03M as of Q2 2026.
  • Creative Planning bought 378 Vir Biotechnology shares in Q2 2026, an estimated $3.6K.
  • Vir Biotechnology made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2615 holding.
  • Creative Planning first reported a position in Vir Biotechnology in Q4 2023 and has held it in 10 quarters since.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.